Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 3
2007 1
2008 2
2010 3
2011 1
2013 4
2014 1
2016 1
2017 3
2018 3
2019 1
2020 1
2021 2
2022 4
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.
Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). Bottai M, et al. RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017. RMD Open. 2017. PMID: 29177080 Free PMC article.
Long-term outcomes in Juvenile Myositis patients.
Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, Targoff IN, Schiffenbauer A, Miller FW, Simmens SJ, Curiel R, Jones OY, Rider LG. Tsaltskan V, et al. Among authors: mamyrova g. Semin Arthritis Rheum. 2020 Feb;50(1):149-155. doi: 10.1016/j.semarthrit.2019.06.014. Epub 2019 Jun 28. Semin Arthritis Rheum. 2020. PMID: 31303436 Free PMC article.
Medications received by patients with juvenile dermatomyositis.
Kishi T, Bayat N, Ward MM, Huber AM, Wu L, Mamyrova G, Targoff IN, Warren-Hicks WJ, Miller FW, Rider LG; Childhood Myositis Heterogeneity Study Group. Kishi T, et al. Among authors: mamyrova g. Semin Arthritis Rheum. 2018 Dec;48(3):513-522. doi: 10.1016/j.semarthrit.2018.03.016. Epub 2018 Mar 28. Semin Arthritis Rheum. 2018. PMID: 29773230 Free PMC article.
Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2023 Sep;75(9):1668-1677. doi: 10.1002/art.42512. Epub 2023 Jul 19. Arthritis Rheumatol. 2023. PMID: 36996276
Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies.
Zhou D, King EH, Rothwell S, Krystufkova O, Notarnicola A, Coss S, Abdul-Aziz R, Miller KE, Dang A, Yu GR, Drew J, Lundström E, Pachman LM, Mamyrova G, Curiel RV, De Paepe B, De Bleecker JL, Payton A, Ollier W, O'Hanlon TP, Targoff IN, Flegel WA, Sivaraman V, Oberle E, Akoghlanian S, Driest K, Spencer CH, Wu YL, Nagaraja HN, Ardoin SP, Chinoy H, Rider LG, Miller FW, Lundberg IE, Padyukov L, Vencovský J, Lamb JA, Yu CY; for MYOGEN Investigators. Zhou D, et al. Among authors: mamyrova g. Ann Rheum Dis. 2023 Feb;82(2):235-245. doi: 10.1136/ard-2022-222935. Epub 2022 Sep 28. Ann Rheum Dis. 2023. PMID: 36171069 Free PMC article.
Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis.
Deakin CT, Bowes J, Rider LG, Miller FW, Pachman LM, Sanner H, Rouster-Stevens K, Mamyrova G, Curiel R, Feldman BM, Huber AM, Reed AM, Schmeling H, Cook CG, Marshall LR, Ll Wilkinson MG, Eyre S, Raychaudhuri S, Wedderburn LR; Juvenile Dermatomyositis Cohort and Biomarker Study, the Childhood Myositis Heterogeneity Study Group, and the Myositis Genetics Consortium (MYOGEN). Deakin CT, et al. Among authors: mamyrova g. Hum Mol Genet. 2022 Jul 21;31(14):2471-2481. doi: 10.1093/hmg/ddac019. Hum Mol Genet. 2022. PMID: 35094092 Free PMC article.
Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA, Yang Q, Gutierrez-Alamillo L, Pak K, Flegel WA, Mammen AL, Rider LG, Casciola-Rosen LA; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2024 Apr;76(4):631-637. doi: 10.1002/art.42768. Epub 2024 Jan 30. Arthritis Rheumatol. 2024. PMID: 38059274
34 results